Discovery of novel indolinone-based,potent, selective and brain penetrant inhibitors of LRRK2 |
| |
| Authors: | Thomas Troxler Paulette Greenidge Kaspar Zimmermann Sandrine Desrayaud Peter Drückes Tatjana Schweizer Daniela Stauffer Giorgio Rovelli Derya R. Shimshek |
| |
| Affiliation: | 1. Novartis Institutes for BioMedical Research, Global Discovery Chemistry, CH-4002 Basel, Switzerland;2. Novartis Institutes for BioMedical Research, Metabolism and Pharmacokinetics, CH-4002 Basel, Switzerland;3. Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry, CH-4002 Basel, Switzerland;4. Novartis Institutes for BioMedical Research, Neuroscience, CH-4002 Basel, Switzerland |
| |
| Abstract: | ![]()
Mutations in leucine-rich repeat kinase-2 (LRRK2) are the most common genetic cause of Parkinson’s disease (PD). The most frequent kinase-enhancing mutation is the G2019S residing in the kinase activation domain. This opens up a promising therapeutic avenue for drug discovery targeting the kinase activity of LRRK2 in PD. Several LRRK2 inhibitors have been reported to date. Here, we report a selective, brain penetrant LRRK2 inhibitor and demonstrate by a competition pulldown assay in vivo target engagement in mice. |
| |
| Keywords: | Leucine-rich repeat kinase 2 LRRK2 LRRK2 inhibitors Kinase inhibitors Parkinson’s disease |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
